# Spain Sacroiliitis Treatment Market > Spain Sacroiliitis Treatment Market Research Report By Type (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation) and By End-user (Hospitals, Clinics, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.4% - **2024:** $ 691.77 Million - **2025:** $ 819.06 Million - **2035:** $ 4,435.2 Million - **Key Players:** AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR) **Report ID:** MRFR/HC/52196-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/spain-sacroiliitis-treatment-market-53958 --- ## Market Summary ## **Spain Sacroiliitis Treatment Market Overview** As per MRFR analysis, the Spain Sacroiliitis Treatment Market Size was estimated at 779.05 (USD Million) in 2023.The Spain Sacroiliitis Treatment Market is expected to grow from 922.4(USD Million) in 2024 to 1,100 (USD Million) by 2035. The Spain Sacroiliitis Treatment Market CAGR (growth rate) is expected to be around 1.614% during the forecast period (2025 - 2035) **Key Spain Sacroiliitis Treatment Market Trends Highlighted** Numerous variables are driving a number of noteworthy trends in the Spanish sacroiliitis treatment market. The increased prevalence of sacroiliitis, which is mostly caused by changes in lifestyle and the escalation of autoimmune illnesses, is one important market driver. Increased diagnosis and treatment options are also a result of the public's and healthcare professionals' increased awareness of sacroiliitis. Effective therapies for sacroiliitis can flourish in Spain as a result of healthcare policies that place a greater emphasis on treating chronic pain illnesses. The incorporation of cutting-edge technology into therapeutic alternatives is creating new market opportunities. Reaching patients using telemedicine is becoming more and more feasible, particularly in rural locations where access to specialists may be restricted. Pharmaceutical firms have an opportunity to get a bigger market share because the Spanish government is also investing in cutting-edge treatments, such as biologics and new anti-inflammatory medications. New avenues for patient care are being created by the combination of these contemporary medicines with traditional treatments. In Spain, the management of sacroiliitis has recently shifted toward multidisciplinary approaches, with medical professionals working together more and more to give all-encompassing care that includes counseling and physical therapy in addition to medication. This pattern reflects a wider recognition that pharmaceutical remedies alone are not enough for effective therapy. Additionally, patients now have additional options for controlling their conditions thanks to the increasing recognition of alternative treatment modalities like yoga and acupuncture. All of these elements support Spain's dedication to enhancing healthcare results and create a dynamic environment in the sacroiliitis treatment market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Spain Sacroiliitis Treatment Market Drivers** **Increasing Prevalence of Sacroiliitis Cases** The increasing prevalence of sacroiliitis in Spain is a significant driver for the Spain [Sacroiliitis Treatment Market](../../../reports/sacroiliitis-treatment-market-6590). According to the Spanish Society of Rheumatology, the incidence of inflammatory spinal diseases, such as sacroiliitis, has shown a gradual increase, estimated at around 20% over the past decade. This rise in cases necessitates advanced treatment options and contributes to the growing demand for specialized therapies. The Spanish government has launched initiatives to promote research on musculoskeletal disorders, potentially increasing funding for Research and Development (R&D) in treatments for conditions like sacroiliitis. Furthermore, organizations such as the Spanish Institute of Health Carlos III are actively conducting studies to assess the burden of these diseases, contributing to a greater awareness and the need for effective treatment solutions in the region. **Rising Awareness of Chronic Pain Management** There is a growing awareness regarding chronic pain management in Spain, particularly among healthcare professionals and the general public. The Spanish government has made strides in educating healthcare providers on the implications of chronic conditions like sacroiliitis. Reports indicate that chronic pain affects approximately 19% of the population, leading to an increased focus on treatment options. This awareness is supported by the work of organizations such as the Spanish Chronic Pain Association, which advocates for comprehensive pain management approaches. As patients become more informed about treatment possibilities, the demand for sacroiliitis therapies continues to rise in the Spain Sacroiliitis Treatment Market. **Advancements in Medical Technology and Treatment Options** Technological advancements in medical treatment options are driving the Spain Sacroiliitis Treatment Market. Innovative therapies, including biologics and targeted drugs, are emerging, offering better efficacy and safety profiles for patients. The Ministry of Health of Spain has been supportive of integrating these advanced treatment modalities into clinical practice, as shown by recent guidelines aimed at enhancing the treatment landscape for inflammatory diseases. Furthermore, Spain ranks high in medical technology patents in Europe, indicating a robust environment for innovation. The collaboration between public health institutions and private companies facilitates the introduction of new solutions for sacroiliitis, catering to an increasing patient population. **Spain Sacroiliitis Treatment Market Segment Insights** **Sacroiliitis Treatment Market Type Insights** The Spain Sacroiliitis Treatment Market is characterized by various types of treatment modalities that cater to the diverse needs of patients suffering from sacroiliitis, a condition often marked by inflammation in the sacroiliac joint. Among these, medications play a vital role, as they encompass a range of anti-inflammatory drugs and analgesics that help manage pain and reduce inflammation, thereby providing immediate relief to patients. Joint injections stand out as a targeted approach, primarily using corticosteroids, which aim to deliver localized relief and minimize systemic side effects, making it preferred for many physicians and patients alike. Additionally, joint fusion is significant in instances where structural stability is required; this surgical intervention aims to fuse the affected joint, significantly reducing pain and improving functionality in chronic cases. On the other hand, radiofrequency denervation is gaining traction, particularly for those seeking a minimally invasive option; this technique uses heat generated by radio waves to disrupt nerve conduction, leading to reduced pain in patients with less invasive treatment intolerance. Electrical stimulation methods are also becoming increasingly popular as they involve the use of electrical impulses to alleviate pain, offering patients a non-pharmacological alternative to manage their symptoms effectively. Factors contributing to the growth of the Spain Sacroiliitis Treatment Market include the increased prevalence of inflammatory joint diseases in the population and the aging demographic, both contributing to a higher demand for effective treatment options. Furthermore, advancements in medical technologies are providing healthcare providers with innovative tools, enhancing the treatment landscape for sacroiliitis. The Spanish government's healthcare policies also support various treatment modalities, promoting access to a broad spectrum of therapies for patients in need, thereby contributing to the overall market development. Overall, as new research emerges and treatment paradigms shift, the market for sacroiliitis interventions will likely continue to evolve, driven by the need for effective and individualized treatment strategies within the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Sacroiliitis Treatment Market****End-use****r Insights** The Spain Sacroiliitis Treatment Market showcases a diverse End-user segmentation, which plays a vital role in catering to the varied healthcare needs across the region. Hospitals are fundamental within this sector, providing comprehensive care and advanced treatment options for individuals suffering from sacroiliitis. Their capacity to integrate specialized medical technologies and skilled healthcare professionals contributes significantly to patient outcomes. Clinics, on the other hand, offer accessible and focused care, catering to the growing demand for outpatient services, which are essential as more patients prefer less invasive options and quicker treatment. Additionally, other facilities, such as rehabilitation centers, are emerging to support recovery, emphasizing holistic treatment approaches that encompass physiotherapy and pain management. This segmentation reflects changing patient preferences and underscores the healthcare landscape's shift towards more targeted and efficient treatment options in Spain. As the population ages and awareness of sacroiliitis increases, the demand within these segments is expected to rise, providing opportunities for improved healthcare delivery and innovation. Taking into account the growing incidence of musculoskeletal disorders, the role of each End-user type will continue to evolve, fostering a collaborative environment that enhances overall care quality in Spain. **Spain Sacroiliitis Treatment Market Key Players and Competitive Insights** The competitive landscape of the Spain Sacroiliitis Treatment Market reflects a dynamic interplay of various pharmaceutical companies striving for a substantial market share while catering to the therapeutic needs associated with this painful inflammatory condition. Incorporating advanced biopharmaceutical developments and targeted therapies, the market is characterized by a range of innovative treatment options aimed at addressing the underlying causes of sacroiliitis. Companies are increasingly focusing on research and development, clinical trials, and strategic partnerships to enhance their product offerings and increase efficiency in treatment protocols. As a result, the Spain Sacroiliitis Treatment Market is experiencing a gradual shift towards more effective, accessible, and patient-centered therapies. Amgen has established a notable footprint in the Spain Sacroiliitis Treatment Market with its advanced portfolio of biologic therapies. This company particularly emphasizes its research initiatives that explore novel mechanisms of action, which support its products aimed at managing chronic inflammatory conditions like sacroiliitis. With a commitment to innovation, Amgen has leveraged its strengths in biotechnology to develop treatments that offer improved efficacy and safety profiles. The company's focus on patient-centric biosimilars in this domain allows it to compete robustly while addressing unmet medical needs within Spain. Moreover, its strategic collaborations and partnerships across the healthcare continuum further enhance its reputation and influence in the regional market. Pfizer holds a competitive edge in the Spain Sacroiliitis Treatment Market through its extensive range of pharmaceutical solutions including anti-inflammatory drugs and treatments specifically designed for rheumatoid arthritis, which are closely aligned with addressing sacroiliitis symptoms. The company benefits from a strong market presence, marked by trusted products that are widely recognized within the healthcare community. Pfizer’s commitment to advancing its therapeutic offerings is evidenced by its active engagement in clinical research and the pursuit of new indications for existing treatments. The company’s history of strategic mergers and acquisitions has significantly bolstered its capabilities in the immunology space, thus enhancing its ability to deliver innovative therapies tailored to the needs of patients and healthcare providers in Spain. As it continues to explore partnerships that align with its vision, Pfizer remains a key player in shaping the treatment landscape for sacroiliitis in the region. **Key Companies in the Spain Sacroiliitis Treatment Market Include** - Amgen - Pfizer - Roche - Gilead Sciences - Johnson & Johnson - Eli Lilly - Merck & Co - Celgene - Biogen - AstraZeneca - AbbVie - Bristol-Myers Squibb - Sanofi - Novartis **Spain Sacroiliitis Treatment****Market****Developments** Recent developments in the Spain Sacroiliitis Treatment Market indicate a growing focus from major pharmaceutical companies such as Amgen, Pfizer, and Roche, on innovating treatment options and expanding market presence. Notably, in September 2023, AbbVie received approval for a new treatment specifically targeting sacroiliitis, which is projected to enhance market competition. Furthermore, Eli Lilly has been actively engaging in research partnerships to develop advanced therapies, responding to the increasing prevalence of sacroiliitis among the Spanish population. The market saw a significant increase in evaluation, reflecting an upward trajectory, impacting investments and research activities in Spain's healthcare sector. Additionally, in August 2023, Gilead Sciences announced a strategic alliance with Johnson and Johnson to collaborate on therapies for inflammatory diseases, including sacroiliitis, signaling a trend towards consolidation within the sector. Over the last two years, notable occurrences included AstraZeneca's expansion of its portfolio in Spain, bolstering its position in the treatment market. Developments like these, along with the heightened focus on patient-centered care, are shaping the dynamics of the Spain Sacroiliitis Treatment Market. **Spain Sacroiliitis Treatment Market Segmentation Insights** **Sacroiliitis Treatment Market Type****Outlook** - Medications - Joint Injections - Joint Fusion - Radiofrequency Denervation - Electrical Stimulation **Sacroiliitis Treatment Market****End-use****r****Outlook** - Hospitals - Clinics - Others ## Market Drivers ### Government Initiatives and Funding Government initiatives aimed at improving healthcare access and funding for chronic pain management are likely to bolster the sacroiliitis treatment market. In Spain, the government has allocated substantial resources to enhance healthcare services, particularly for musculoskeletal disorders. Recent reports suggest that public health expenditure on chronic pain management has increased by 15% in the past year. This financial support facilitates the development and distribution of innovative treatment options, including biologics and advanced imaging techniques. Furthermore, public awareness campaigns are being launched to educate patients about sacroiliitis, which may lead to earlier diagnosis and treatment. As a result, government initiatives and funding are expected to play a pivotal role in shaping the future of the sacroiliitis treatment market. ### Increasing Prevalence of Sacroiliitis The rising incidence of sacroiliitis in Spain is a crucial driver for the sacroiliitis treatment market. Recent studies indicate that the prevalence of inflammatory back pain, which includes sacroiliitis, has increased by approximately 20% over the last decade. This trend is likely attributed to lifestyle changes, including sedentary behavior and increased stress levels. As more individuals are diagnosed with this condition, the demand for effective treatment options is expected to grow. Healthcare providers are increasingly focusing on early diagnosis and intervention, which may lead to a surge in treatment options available in the market. Consequently, the increasing prevalence of sacroiliitis is anticipated to significantly impact the growth trajectory of the sacroiliitis treatment market in Spain. ### Rising Demand for Personalized Medicine The shift towards personalized medicine is emerging as a significant driver for the sacroiliitis treatment market. Patients are increasingly seeking tailored treatment plans that consider their unique genetic, environmental, and lifestyle factors. In Spain, the trend towards personalized healthcare has gained momentum, with a reported increase of 25% in the use of targeted therapies for chronic conditions. This approach not only enhances treatment efficacy but also minimizes adverse effects, leading to improved patient satisfaction. As healthcare providers adopt more individualized treatment strategies for sacroiliitis, the market is likely to witness a surge in demand for customized therapies. This growing emphasis on personalized medicine is expected to shape the future landscape of the sacroiliitis treatment market. ### Technological Advancements in Diagnostics Technological advancements in diagnostic tools are transforming the landscape of the sacroiliitis treatment market. Innovations such as MRI and CT imaging have significantly improved the accuracy of sacroiliitis diagnosis, allowing for earlier and more effective treatment interventions. In Spain, the adoption of these advanced diagnostic technologies has increased by approximately 30% over the last few years. Enhanced diagnostic capabilities enable healthcare professionals to identify sacroiliitis more effectively, leading to timely treatment and better patient outcomes. This trend is likely to drive the demand for various treatment modalities, including pharmacological and non-pharmacological approaches. Consequently, the integration of advanced diagnostic technologies is expected to be a key driver in the growth of the sacroiliitis treatment market. ### Collaboration Between Healthcare Providers Collaboration among healthcare providers is becoming increasingly vital in addressing the complexities of sacroiliitis treatment. In Spain, multidisciplinary teams comprising rheumatologists, physiotherapists, and pain specialists are working together to develop comprehensive treatment plans. This collaborative approach is likely to enhance patient care and improve treatment outcomes. Recent surveys indicate that 70% of healthcare professionals believe that teamwork in managing sacroiliitis leads to better patient satisfaction and adherence to treatment protocols. As healthcare systems continue to evolve, the emphasis on collaborative care is expected to drive the growth of the sacroiliitis treatment market. By fostering communication and cooperation among various specialists, the market may see an increase in innovative treatment strategies and improved patient management. ## Future Outlook The [Sacroiliitis Treatment Market](https://www.marketresearchfuture.com/reports/sacroiliitis-treatment-market-6590) in Spain is projected to grow at an 18.4% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in biologics and targeted therapies for enhanced efficacy - Expansion of patient education programs to improve treatment adherence By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Medications (Largest) vs. Joint Injections (Fastest-Growing) In the Spain sacroiliitis treatment market, the segment distribution reveals that Medications hold the largest share due to their widespread acceptance and efficacy. Joint Injections, meanwhile, are gaining traction among physicians and patients alike, contributing significantly to their emerging position in the market. This dynamic competition between established treatment options and newer intervention methods highlights the evolving landscape of options available for managing sacroiliitis. Growth trends indicate a shift towards personalized medicine, with Medications remaining dominant due to consistent demand. Joint Injections are on the rise, attributed to their effective pain relief capabilities and minimal invasiveness. Factors such as increasing patient awareness, advancements in injection techniques, and a growing emphasis on outpatient treatments are fueling the expansion of this segment. Medications (Dominant) vs. Joint Injections (Emerging) Medications are the dominant force in the Spain sacroiliitis treatment market thanks to their established role in therapeutic protocols and favorable patient outcomes. These solutions encompass a range of anti-inflammatory drugs and analgesics tailored to alleviate pain and reduce inflammation effectively. On the other hand, Joint Injections are emerging as a viable alternative, particularly for patients seeking targeted treatment options. This method, known for delivering corticosteroids or hyaluronic acid directly into the joint space, has become popular due to its rapid pain relief and ability to improve mobility. The interplay between these segments demonstrates a balancing act between established treatments and innovative approaches. ### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the Spain sacroiliitis treatment market, hospitals command the largest share, primarily due to their advanced facilities and comprehensive treatment options. As primary healthcare providers, they cater to a vast population, ensuring a steady influx of patients requiring diagnostic and therapeutic services for sacroiliitis. Clinics, while smaller in market share compared to hospitals, are rapidly gaining traction, highlighted by increased patient referrals and a growing preference for outpatient care. The growth trends within this segment reveal that clinics are emerging as a significant player, driven by the demand for minimally invasive procedures and quicker recovery times. The perception of clinics as more accessible and cost-effective alternatives to hospitals is also propelling this rise. Additionally, advancements in telemedicine and outpatient treatment options have encouraged patients to opt for clinic-based care, indicating a transformation in treatment delivery methods. Hospitals (Dominant) vs. Clinics (Emerging) Hospitals play a dominant role in the Spain sacroiliitis treatment market, showcasing advanced medical technology and extensive specialist teams. They provide comprehensive care, including diagnostic imaging, pain management, and surgical interventions, which are vital for patients with complex conditions. Conversely, clinics are emerging as a preferred option for many patients seeking efficiency and affordability in their treatment. They often offer tailored care plans and specialized therapies focusing on rehabilitation and pain relief, making them appealing for patients who might prefer an outpatient setting. The rise of clinics reflects a growing trend towards integrated care models, prioritizing patient preferences and streamlining treatment pathways in the management of sacroiliitis. ## Competitive Benchmarking The sacroiliitis treatment market in Spain is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie Inc (US), Amgen Inc (US), and Bristol-Myers Squibb Company (US) are actively engaged in enhancing their product offerings and expanding their market presence. AbbVie Inc (US) has positioned itself as a leader in immunology, focusing on the development of novel therapies that target the underlying mechanisms of sacroiliitis. This strategic emphasis on innovation is indicative of a broader trend among competitors to leverage advanced research and development capabilities to meet the evolving needs of patients.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This collective influence of key players fosters a dynamic environment where competition is not solely based on pricing but also on the quality and efficacy of treatment options. In October Amgen Inc (US) announced a strategic partnership with a leading Spanish healthcare provider to enhance access to its innovative therapies for sacroiliitis. This collaboration is expected to facilitate better patient outcomes through localized treatment options and improved healthcare delivery. Such partnerships are crucial as they not only expand market reach but also align with the growing emphasis on personalized medicine. In September Bristol-Myers Squibb Company (US) launched a new clinical trial aimed at evaluating the long-term efficacy of its latest biologic therapy for sacroiliitis. This initiative underscores the company's commitment to advancing treatment options and addressing unmet medical needs. The results of this trial could potentially reshape treatment protocols and solidify the company's position in the market. In November Johnson & Johnson (US) unveiled a digital health platform designed to support patients with sacroiliitis in managing their condition more effectively. This platform integrates telehealth services and personalized treatment plans, reflecting a significant shift towards digitalization in healthcare. The strategic importance of this move lies in its potential to enhance patient engagement and adherence to treatment regimens, thereby improving overall health outcomes. As of November the competitive trends in the sacroiliitis treatment market are increasingly defined by digital transformation, sustainability initiatives, and the integration of artificial intelligence in treatment protocols. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve, with a pronounced shift from price-based competition to a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This evolution suggests that companies that prioritize these areas will be better positioned to thrive in the changing landscape. ## Recent News & Developments Recent developments in the Spain Sacroiliitis Treatment Market indicate a growing focus from major pharmaceutical companies such as Amgen, Pfizer, and Roche, on innovating treatment options and expanding market presence. Notably, in September 2023, AbbVie received approval for a new treatment specifically targeting sacroiliitis, which is projected to enhance market competition. Furthermore, Eli Lilly has been actively engaging in research partnerships to develop advanced therapies, responding to the increasing prevalence of sacroiliitis among the Spanish population. The market saw a significant increase in evaluation, reflecting an upward trajectory, impacting investments and research activities in Spain's healthcare sector. Additionally, in August 2023, Gilead Sciences announced a strategic alliance with Johnson and Johnson to collaborate on therapies for inflammatory diseases, including sacroiliitis, signaling a trend towards consolidation within the sector. Over the last two years, notable occurrences included AstraZeneca's expansion of its portfolio in Spain, bolstering its position in the treatment market. Developments like these, along with the heightened focus on patient-centered care, are shaping the dynamics of the Spain Sacroiliitis Treatment Market. ## Report Scope | MARKET SIZE 2024 | 691.77(USD Million) | | --- | --- | | MARKET SIZE 2025 | 819.06(USD Million) | | MARKET SIZE 2035 | 4435.2(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.4% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR) | | Segments Covered | Type, End-User | | Key Market Opportunities | Emerging biologics and personalized therapies enhance treatment options in the sacroiliitis treatment market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition in the sacroiliitis treatment market amid evolving regulatory frameworks. | | Countries Covered | Spain | ## Frequently Asked Questions **Q: What was the market valuation of the Spain sacroiliitis treatment market in 2024?** A: The market valuation was $691.77 Million in 2024. **Q: What is the projected market valuation for the Spain sacroiliitis treatment market by 2035?** A: The projected valuation for 2035 is $4435.2 Million. **Q: What is the expected CAGR for the Spain sacroiliitis treatment market during the forecast period 2025 - 2035?** A: The expected CAGR is 18.4% during the forecast period 2025 - 2035. **Q: Which segment had the highest valuation in the Spain sacroiliitis treatment market in 2024?** A: Medications had the highest valuation at $885.0 Million in 2024. **Q: What are the key players in the Spain sacroiliitis treatment market?** A: Key players include AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Pfizer Inc, Roche Holding AG, and Sanofi S.A. **Q: How much did joint injections contribute to the market in 2024?** A: Joint injections contributed $660.0 Million to the market in 2024. **Q: What is the projected growth for the medications segment by 2035?** A: The medications segment is expected to grow significantly, reaching a projected valuation of $138.35 Million in 2035. **Q: Which end-user segment had the highest valuation in 2024?** A: Hospitals had the highest valuation among end-user segments at $1765.56 Million in 2024. **Q: What is the expected market size for clinics in the Spain sacroiliitis treatment market by 2035?** A: The expected market size for clinics is projected to reach $207.53 Million by 2035. **Q: How does the performance of the electrical stimulation segment compare to others in 2024?** A: The electrical stimulation segment had a valuation of $270.0 Million in 2024, indicating a competitive position within the market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/spain-sacroiliitis-treatment-market-53958*